Akebia Ther (AKBA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Akebia Ther (AKBA) has a cash flow conversion efficiency ratio of 0.955x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($31.13 Million) by net assets ($32.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AKBA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Akebia Ther - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Akebia Ther's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Akebia Ther Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akebia Ther ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bhansali Engineering Polymers Limited
NSE:BEPL
|
0.036x |
|
PT Estee Gold Feet Tbk
JK:EURO
|
-0.067x |
|
Microbio Co Ltd
TWO:4128
|
-0.010x |
|
Ganesha Ecosphere Limited
NSE:GANECOS
|
0.074x |
|
Highlight Tech
TWO:6208
|
0.085x |
|
Sampo Corp
TW:1604
|
0.025x |
|
Shandong Sino-Agri United Biotechnology Co Ltd
SHE:003042
|
-0.034x |
|
Atha Energy Corp.
V:SASK
|
0.006x |
Annual Cash Flow Conversion Efficiency for Akebia Ther (2012–2025)
The table below shows the annual cash flow conversion efficiency of Akebia Ther from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Akebia Ther worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $32.61 Million | $67.99 Million | 2.085x | +152.22% |
| 2024-12-31 | $-49.19 Million | $-40.66 Million | 0.827x | +8.12% |
| 2023-12-31 | $-30.58 Million | $-23.38 Million | 0.765x | +105.47% |
| 2022-12-31 | $5.23 Million | $-73.15 Million | -13.987x | -309.22% |
| 2021-12-31 | $74.01 Million | $-252.97 Million | -3.418x | -666.73% |
| 2020-12-31 | $247.62 Million | $-110.39 Million | -0.446x | +31.64% |
| 2019-12-31 | $394.76 Million | $-257.44 Million | -0.652x | -325.38% |
| 2018-12-31 | $635.93 Million | $-97.49 Million | -0.153x | +67.42% |
| 2017-12-31 | $119.33 Million | $-56.16 Million | -0.471x | -155.36% |
| 2016-12-31 | $68.12 Million | $57.91 Million | 0.850x | +312.48% |
| 2015-12-31 | $131.00 Million | $-52.41 Million | -0.400x | -51.50% |
| 2014-12-31 | $104.08 Million | $-27.48 Million | -0.264x | +28.33% |
| 2013-12-31 | $30.76 Million | $-11.33 Million | -0.368x | -113.69% |
| 2012-12-31 | $-2.68 Million | $-7.21 Million | 2.691x | -- |
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and … Read more